Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2023-01-12 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
华英证券有限责任公司关于深圳信立泰药业股份有限公司2022年度持续督导现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年度持续督导现场检查报告" which translates to "2022 Annual Continuous Supervision On-site Inspection Report" by the sponsor 华英证券有限责任公司 for 深圳信立泰药业股份有限公司. It details the on-site inspection of company governance, internal controls, information disclosure, protection of company interests, use of raised funds, performance, and other important matters for the year 2022. The document includes detailed findings and compliance checks but does not contain full financial statements or comprehensive financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It is a standalone audit or inspection report focusing on regulatory compliance and internal controls, consistent with an Audit Report / Information (AR). The document length is 3636 characters, which is relatively short but contains substantive content rather than just an announcement or certification. Therefore, it fits best under the Audit Report / Information (AR) category. FY 2022
2023-01-12 Chinese
关于S086临床试验进展的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the progress of a Phase III clinical trial for their drug S086. It provides detailed information about the clinical trial results, safety data, and future plans for the drug development. The document is relatively short (1473 characters) and is focused on disclosing clinical trial progress rather than financial data or regulatory filings. It is not an annual or interim financial report, nor is it a regulatory filing or certification. It is a specific announcement about clinical trial progress, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit into other specific financial or corporate categories.
2023-01-11 Chinese
关于SAL0133片获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the approval of a clinical trial for their drug SAL0133. It contains no financial data, no financial statements, and no detailed report content. It is a regulatory announcement about a clinical trial approval from the National Medical Products Administration. The document is short (1448 characters) and serves as an official notification to investors about a regulatory milestone, not a financial report or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-01-03 Chinese
关于SAL008注射液获得临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a clinical trial for a drug (SAL008 injection). It includes details about the drug, its mechanism, and regulatory approval from the National Medical Products Administration. The document is short (1201 characters) and is an announcement of a regulatory approval event, not a financial report or detailed management discussion. It does not contain financial statements, earnings data, or governance changes. It is not a report publication announcement since it does not mention any report being attached or published. The content fits best under a general regulatory announcement category, as it informs investors about a significant regulatory milestone related to clinical trials but does not fit into more specific categories like earnings, management changes, or capital updates.
2022-12-29 Chinese
关于SAL0133片药品临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the acceptance of a clinical trial application for a new drug (SAL0133). It includes details about the drug, regulatory acceptance by the National Medical Products Administration, and disclaimers about the drug development process and risks. There are no financial statements, earnings data, or management discussion of financial results. The document is an official announcement about regulatory acceptance of a clinical trial application, not a financial report or management report. It fits best under Regulatory Filings (RNS) as it is a regulatory announcement that does not fit other specific categories.
2022-12-20 Chinese
关于SAL003临床试验进展的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen Salubris Pharmaceuticals Co., Ltd. regarding the progress of a clinical trial for a drug candidate SAL003. It provides details about the clinical trial phase, preliminary results, and future plans. The document is relatively short (1440 characters) and is an announcement of clinical trial progress rather than a financial report or regulatory filing. It does not contain financial data, management changes, voting results, or other categories related to corporate filings. It is an announcement of a clinical development progress, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-12-16 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.